Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Luhua Wang, MD
Cancer Hospital of Chinese Academy of Medical Science
Principal Investigator - Nabil Saba, MD
Department of Hematology and Medical Oncology, Emory University
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
133 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Brussels, Belgium
- Research Site
Charleroi, Belgium
- Research Site
Liège, Belgium
- Research Site
Namur, Belgium
- Research Site
Barretos, Brazil
- Research Site
Fortaleza, Brazil
- Research Site
Porto Alegre, Brazil
- Research Site
Porto Alegre, Brazil
- Research Site
Rio de Janeiro, Brazil
- Research Site
São José do Rio Preto, Brazil
- Research Site
Vitória, Brazil
- Research Site
Barrie, Ontario, Canada
- Research Site
Greater Sudbury, Ontario, Canada
- Research Site
Anyang, China
- Research Site
Beijing, China
- Research Site
Beijing, China
- Research Site
Bengbu, China
- Research Site
Changsha, China
- Research Site
Changzhi, China
- Research Site
Chengdu, China
- Research Site
Chongqing, China
- Research Site
Fuzhou, China
- Research Site
Fuzhou, China
- Research Site
Guangzhou, China
- Research Site
Guangzhou, China
- Research Site
Hangzhou, China
- Research Site
Hefei, China
- Research Site
Huai'an, China
- Research Site
Jieyang, China
- Research Site
Jinan, China
- Research Site
Kunming, China
- Research Site
Liangyugang, China
- Research Site
Nantong, China
- Research Site
Qingdao, China
- Research Site
Quanzhou, China
- Research Site
Shenzhen, China
- Research Site
Tianjin, China
- Research Site
Xi'an, China
- Research Site
Xuzhou, China
- Research Site
Yangzhou, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Oct 2020
- Primary completion
- 30 Jun 2027
- Completion
- 30 Jun 2027
- Last update posted
- 13 May 2026
- Registered enrollment
- 640
- Registry id
- NCT04550260
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.